Abstract: A wave power generator comprising a chain drive arrangement. The Wave power generator comprising a float connected to one end of a retractable chain and a retractable device connected to an opposite end of the retractable chain.

Abstract: A wave power generator comprising a chain drive arrangement. The wave power generator comprising a float connected to one end of a retractable chain and a retractable device connected to an opposite end of the retractable chain.

Abstract: A wave power generator comprising a chain drive arrangement. The wave power generator comprising a float connected to one end of a retractable chain and a retractable device connected to an opposite end of the retractable chain.

Abstract: A network device having text-based command language functions that are accessible via the network, includes a receiver for receiving a network protocol command sent through the network and having a text-based command attached thereto. The receiver determines whether a text-based command is attached to the network protocol command, and an interface extracts the text-based command from the network protocol command.

Abstract: The present invention provides methods, compositions, and kits useful for modulating insulin/glucose homeostasis in a subject by modulating CAP/SORBS1. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate insulin/glucose homeostasis. Methods of the invention can involve assaying test agent binding to CAP/SORBS1 polypeptides or polynucleotides. Alternatively, test agents can be screened for their ability to alter the level of CAP/SORBS1 polypeptides, polynucleotides, or action.

Abstract: Animal models, kits, and methods for diagnosis and treatment of Cornelia de Lange Syndrome are disclosed. In especially preferred aspects, altered gene expression of selected genes is correlated with a NIPBL+/? genotype to thereby identify surrogate markers, which may then be used to diagnose Cornelia de Lange Syndrome.

Abstract: Glycosylphosphatidylinositol-(GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer—both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts—whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues.